Niagen Bioscience Reports Results for Quarter Ended June 30, 2026

What Happened

• On August 4, 2026, Niagen Bioscience, Inc. (NAGE) filed a Form 8-K to announce its earnings for the quarter ended June 30, 2026 via a press release (Exhibit 99.1).
• The company also made a corporate/earnings presentation available on its website and included it as Exhibit 99.2 under Regulation FD disclosure.
• The filing was signed by Chief Financial Officer Ozan Pamir.

Key Details

• Filing date: August 4, 2026 (Form 8-K Items 2.02 and 7.01).
• Press release announcing quarterly results attached as Exhibit 99.1.
• Corporate presentation released on the company website and attached as Exhibit 99.2 (Regulation FD disclosure).
• Signature: Ozan Pamir, Chief Financial Officer, on behalf of Niagen Bioscience.

Why It Matters

• The 8-K signals that the company has published its latest quarterly financial results and investor materials; these exhibits are the primary source for revenue, net income/loss, EPS, guidance and other metrics investors need to assess performance.
• Posting the presentation under Regulation FD ensures the information was broadly distributed to the market. Retail investors should review the attached press release and presentation (or the company website) for the specific financial figures and any management commentary, and watch for follow-up filings (e.g., 10-Q) for full financial statements.